A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Condition(s):High-risk Smoldering Multiple MyelomaLast Updated:January 27, 2020Completed
Hide Studies Not Open or Pending
Condition(s):High-risk Smoldering Multiple MyelomaLast Updated:January 27, 2020Completed
Condition(s):Multiple MyelomaLast Updated:February 9, 2018Terminated
Condition(s):Multiple MyelomaLast Updated:April 17, 2014Terminated
Condition(s):Multiple MyelomaLast Updated:September 10, 2021Completed
Condition(s):Multiple MyelomaLast Updated:March 24, 2021Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:March 7, 2023Completed
Condition(s):AL AmyloidosisLast Updated:March 10, 2017Completed
Condition(s):Multiple MyelomaLast Updated:July 2, 2010Completed
Condition(s):Multiple MyelomaLast Updated:June 16, 2022Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:July 27, 2022Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.